



Advances in Penile Cancer Research from the Bench Side to the Patients

Guest Editors:

Dr. Jad Chahoud

Department of Genitourinary
Oncology, H. Lee Moffitt Cancer
Center and Research Institute,
Tampa, FL 33612, USA

Dr. Philippe E. Spiess

Department of Genitourinary
Oncology, H. Lee Moffitt Cancer
Center and Research Institute,
Tampa, FL 33612, USA

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

Dear Colleagues,

Penile cancer is a rare and deadly cancer that affects more than 30,000 patients around the globe every year. Over the past two decades we have seen limited improvement in the clinical outcomes of patients with advanced penile cancer.

In this Special Issue we aim to highlight all advances, covering benchside to bedside efforts, that have been made in penile cancer, in hope of improving the clinical outcomes of patients with this rare and challenging cancer.

We aim to include papers focusing on advances in preclinical specific penile cancer models as well as molecular, viral, and immune pathways related to penile cancer oncogenesis that have led to our better understanding of the disease development.

We will also include papers highlighting advances in chemotherapies, vaccine, as well as immune-based and targeted therapies for patients with localized and advanced penile cancer. Papers highlighting advances in radiation and surgical therapies will be welcomed.

Finally, we will showcase research focused on patient-centered approaches with advances in patient-reported outcome and quality-of-life research.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)